Abstract:
OBJECTIVE To evaluate the therapeutic effects of Scutellariae Radix and Forsythiae Fructus at different compatibility ratios in a mouse model of gouty nephropathy, with a focus on the mechanisms involving the NLRP3/IL-1β/TGF-β1 signaling pathway.
METHODS Mice were randomly assigned to six groups: blank control, model group, positive control(allopurinol) group, and three Scutellariae Radix-Forsythiae Fructus groups with compatibility ratios of 1∶1, 2∶3, and 1∶2. Gouty nephropathy was induced in all groups except the blank group by oral administration of adenine(100 mg·kg−1) and potassium oxonate(200 mg·kg−1) suspension for 3 weeks. From 8th day of modeling, each treatment group received the corresponding drug intervention for 14 consecutive days. Renal function parameters, along with serum and hepatic xanthine oxidase(XOD) and adenosine deaminase(ADA) activities, were assessed biochemically. Renal histopathology was examined via HE and Masson staining, while apoptosis was detected by TUNEL assay. The protein expression of NLRP3, IL-1β, and TGF-β1 was evaluated using immunofluorescence and immunohistochemistry. Levels of TNF-α, IL-1β, IL-6, IL-18, and TGF-β1 in renal tissue were measured by ELISA.
RESULTS Compared with the model group, all Scutellariae Radix-Forsythiae Fructus treatment groups exhibited increased body weight gain, reduced 24-hour urinary protein, serum uric acid(UA), blood urea nitrogen(BUN), serum creatinine(Scr), and kidney index, along with elevated urinary UA excretion. Renal histopathological injury, collagen deposition, and apoptosis were also alleviated. Furthermore, protein expression of NLRP3, IL-1β, and TGF-β1 was downregulated, and levels of renal TNF-α, IL-6, IL-18, IL-1β, and TGF-β1 were reduced. The most significant improvements were observed in the 1∶2 Scutellariae Radix-Forsythiae Fructus group.
CONCLUSION The 1∶2 combination of Scutellariae Radix and Forsythiae Fructus provide the most pronounced renoprotective effect in GN mice, likely mediated through suppression of the NLRP3/IL-1β/TGF-β1 signaling pathway.